IP Library Granted Patent US 10,568,568
Granted Patent B2
US 10,568,568 · App. 14/838,241 · Granted Feb 25, 2020

Methods for immune globulin administration

Inventors: Anish Bhatnagar (Redwood City, CA); Anthony D. Wondka (San Ramon, CA)
Assignee: CAPNIA, INC.
A61B5/4848G01N33/497G01N2033/4975
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,568,568
App. No.
14/838,241
Granted
Feb 25, 2020
Kind
B2
Abstract

Methods for administering immune globulin and devices for use thereof. The methods may generally include measuring a patient's hemolysis levels and determining whether the patient is suitable for immune globulin treatment, determining whether immune globulin treatment should be continued, and/or determining if the dose needs to be changed.

Claims (6)

1. A method of adjusting immune globulin administration comprising:

isolating a sample volume from a breath of the patient using a portable breath analyzer; and

diverting a continued flow of air to displace the isolated sample volume through a gas measurement component of the portable breath analyzer to measure an end-tidal carbon monoxide level in the isolated sample volume, wherein the end-tidal carbon monoxide level determines a hemolysis level of the patient, and

wherein in response to determining a high level of hemolysis, forego administering immune globulin to the patient, the high level of hemolysis being determined by the end-tidal carbon monoxide level measurement being greater than 2 ppm, and

wherein in response to determining a low level of hemolysis, administering immune globulin to the patient, the low level of hemolysis being determined by the end- tidal carbon monoxide level measurement being less than 1 ppm.

2. The method of claim 1 , further comprising in response to determining a moderate level of hemolysis is present, administering immune globulin at a lower dose than if a low level of hemolysis was determined, wherein the moderate level of hemolysis is an end-tidal carbon monoxide level measurement between 1 and 2 ppm.

Assignments (4)
SECURITY INTEREST Recorded Dec 17, 2024
From: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069613/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2018
From: SOLENO THERAPEUTICS, INC.
To: CAPNIA, INC.
Reel/Frame 047488/0613 →
CHANGE OF NAME Recorded Nov 17, 2017
From: CAPNIA, INC.
To: SOLENO THERAPEUTICS, INC.
Reel/Frame 044784/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2015
From: BHATNAGAR, ANISH; WONDKA, ANTHONY D.
To: CAPNIA, INC.
Reel/Frame 036443/0533 →
Continuity (2)
Provisional Application 62042762 · Aug 27, 2014
Related Publication 20160060355A1 · Mar 3, 2016